UCB will pay more than $34 million for its illegally promoting Keppra, an epilepsy drug, in the treatment of headaches and pain. The FDA approved Keppra to treat seizures in epileptic patients in 1995. A business plan that was included in the government’s sentencing memorandum showed migraine and other off-label uses would likely bring UCB greater profits, which prompted the drugmaker to sponsor and promote studies that Keppra prevented migraines.

The company, which pled guilty to a misdemeanor, will pay $7.55 million in criminal fines, $1.1 million forfeiture and $25.7 in a civil settlement. Two whistleblowers will share a reward of $2.8 million.

Read the entire article, “UCB Pays $34 Million and Pleads Guilty in Epilepsy Drug Fraud Case”